Stockscreener 앱 받기
7.71
1.78%
-0.14
시간 외 거래:
7.71
전일 마감가:
$7.85
열려 있는:
$7.82
하루 거래량:
208.63K
Relative Volume:
0.68
시가총액:
$321.37M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.87%
1개월 성능:
-21.08%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$7.4364
$7.96
1주일 범위
$7.25
$8.1108
52주 변동 폭
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
1000 WINTER ST, SUITE 1200, WALTHAM
ZBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
7.71 | 321.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma Targets Key 2025 Milestones For Obexelimab In Autoimmune Diseases - BERNAMA
ZENAS BIOPHARMA TARGETS KEY 2025 MILESTONES FOR OBEXELIMAB IN AUTOIMMUNE DISEASES - BERNAMA
ZENAS BIOPHARMA ANNOUNCES KEY 2024 ACCOMPLISHMENTS AND 2025 BUSINESS OBJECTIVES TO SUPPORT THE GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF THERAPIES FOR AUTOIMMUNE DISEASES - BERNAMA
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives - Marketscreener.com
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 - GlobeNewswire
Wolfe Research Initiates Coverage of Zenas BioPharma (ZBIO) with Outperform Recommendation - MSN
Zenas BioPharma initiated with an Outperform at Wolfe Research - MSN
Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target - Marketscreener.com
Zenas Biopharma To Present At Guggenheim SMID Cap Biotech Conference On Feb 5 - BERNAMA
ZENAS BIOPHARMA TO PRESENT AT THE GUGGENHEIM SMID CAP BIOTECH CONFERENCE - BERNAMA
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Zenas BioPharma Takes Center Stage: Key Revelations Expected at Major Biotech Summit - StockTitan
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
Zenas BioPharma initiated with a Buy at H.C. Wainwright - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of Zenas BioPharma (ZBIO) with Buy Recommendation - MSN
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
H.C. Wainwright starts Zenas stock with Buy rating, eyes Obexelimab’s role in autoimmune treatment - Investing.com Australia
Guggenheim maintains buy on ZBIO shares, sees strong drug potential By Investing.com - Investing.com Canada
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley - Yahoo Finance
Zenas BioPharma CEO Leon O. Moulder Jr. purchases $718,100 in stock - Investing.com
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon O. Moulder Jr. acquires shares worth $148,925 - Investing.com
Zenas BioPharma Inc. (ZBIO) Quarterly 10-Q Report - Quartz
FMR LLC Acquires New Stake in Zenas BioPharma Inc - GuruFocus.com
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Raises $259M in IPO, Advances Phase 3 Trial Amid Growing R&D Investment | ZBIO Stock News - StockTitan
Zenas BioPharma Completes Targeted Enrollment of the Phase - GlobeNewswire
Zenas BioPharma Hits Milestone: Completes Enrollment in Largest-Ever IgG4-RD Trial | ZBIO Stock News - StockTitan
Zenas BioPharma To Attend Upcoming Healthcare Investor Conferences - BERNAMA
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences - BERNAMA
TSX Global Base Metals EW Index (TXBE) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Arm Holdings Plc ADR (ARM-Q) QuotePress Release - The Globe and Mail
TSX Industrials EW Index (TXIE) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Biopharma financing drops in Q3, but is outpacing last two years - BioWorld Online
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
| ENRIGHT PATRICK G | Director |
Sep 16 '24 |
Buy |
17.00 |
440,000 |
7,480,000 |
774,530 |
| Nunn Jason Raleigh | Director |
Sep 16 '24 |
Buy |
17.00 |
882,352 |
14,999,984 |
1,946,564 |
1.09%
자본화:
|
볼륨(24시간):